MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Cost of Revenue 2011-2026 | SWAV
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95.4 M | 65 M | 41.4 M | 21 M | 17.2 M | 7.25 M | 2.84 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95.4 M | 2.84 M | 35.7 M |
Quarterly Cost of Revenue ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.2 M | 24.5 M | 24.5 M | 21.1 M | - | 17.9 M | 16.7 M | 12.9 M | - | 10.9 M | 9.93 M | 7.89 M | - | 5.28 M | 3.59 M | 5.65 M | - | 4.4 M | 4.13 M | 3.07 M | - | 1.97 M | 1.18 M | 794 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 794 K | 10.8 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M |  USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 13.38 | 2.29 % | $ 1.81 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.28 | 1.86 % | $ 123 M |  France |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.6 | -1.96 % | $ 37.3 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.08 | -1.16 % | $ 314 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
14 M | $ 25.74 | -1.0 % | $ 218 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 90.74 | -3.16 % | $ 12.3 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.08 | -1.89 % | $ 1.26 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 5.16 | -5.84 % | $ 1.09 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.14 | -4.3 % | $ 355 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.55 | -2.68 % | $ 378 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.04 | -3.7 % | $ 17.6 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.79 | -2.85 % | $ 1.14 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 61.29 | -3.34 % | $ 3.34 B |  Britain |
 |
Inspire Medical Systems
INSP
|
133 M | $ 55.11 | 0.07 % | $ 1.62 B | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.35 | 2.69 % | $ 64 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 84.64 | -0.83 % | $ 2.94 B | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.23 | -4.3 % | $ 50 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 82.28 | -1.41 % | $ 48.1 B | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 3.4 | 1.8 % | $ 502 M | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
NanoVibronix
NAOV
|
2.4 M | - | - | $ 1.08 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.82 | -1.19 % | $ 34.3 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Natus Medical Incorporated
NTUS
|
197 M | - | 1.94 % | $ 1.05 B | USA |
 |
Orthofix Medical
OFIX
|
256 M | $ 11.91 | -3.33 % | $ 472 M |  Curacao |